US Nuclear Strategic Partner Pulmostics is Now Conducting Breast Cancer Clinical Trials
US Nuclear's strategic partner, Pulmostics Ltd, is advancing early breast cancer detection through innovative breath analysis technology. This non-invasive method aims to match or exceed the sensitivity of traditional mammograms. Currently, Pulmostics is conducting clinical trials at Christus Muguerza hospital in Monterrey, Mexico. With approximately 685,000 breast cancer deaths worldwide in 2022, early detection could significantly improve outcomes. The collaboration with Music Beats Cancer seeks to fund these trials and provide free diagnoses to more women.
- Partnership with Pulmostics could revolutionize breast cancer screening.
- Breath analysis technology offers a non-invasive, painless alternative to traditional mammograms.
- Clinical trials underway at a reputable hospital in Monterrey, Mexico.
- Potential to detect breast cancer with equal or greater sensitivity than current gold standards.
- Clinical trial results are still pending, introducing uncertainty.
- Dependence on external funding from charity for trial expansion and free diagnoses.
LOS ANGELES, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – US Nuclear’s (OTC-QB: UCLE) strategic partner Pulmostics Ltd is a biotech start-up devoted to early screening women for breast cancer using innovative breath analysis technology that proved to be a fast, economical, painless non-invasive system to screen for breast cancer and other cancers. A technology that is sorely needed in most countries in the world.
Worldwide, there were 685,000 breast cancer deaths in 2022. These women were mourned by husbands, brothers, children and grand-children. Tragically, many of these deaths could have been prevented were they detected early enough. Globally, most breast cancer cases are detected at stage 3 or later. At this stage of the disease, a woman has a less than
Pulmostics is now conducting clinical trials with Christus Muguerza, the preeminent private hospital in Monterrey, Mexico, to confirm that breath analysis can detect the presence of breast cancer with the same or better sensitivity as a mammogram, the current gold standard. Imagine a world without patients disrobing and without mammogram discomfort. Just exhale, and you and your doctor have your answers.
Pulmostics is teamed with Music Beats Cancer, a 501 c-3 charity to raise funds to further expand the trials and provide free diagnoses to more women.
Please share this message with your friends and family. Breast cancer touches all of us. Your help can save women’s lives.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com
CONTACT:
US Nuclear Corp. (OTC-QB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Richard Landry, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com
FAQ
What is the purpose of US Nuclear's partnership with Pulmostics Ltd?
What are the main features of the breath analysis technology?
Where are the clinical trials for this technology being conducted?
What is the expected impact of early breast cancer detection?
What is the stock symbol for US Nuclear?
